Researchers have developed a novel mouse model for leukemia that reveals critical information about the mechanisms involved in leukemia progression and provides a model system for evaluation of new drugs for treatment of leukemia.

The research has utilized a technique that allows induction and study of a key oncoprotein in adult mice.
Previously, it was difficult to investigate this oncoprotein in the mouse, as the expression of this gene is associated with embryonic lethality, or death of the developing mouse in utero.

Acute myeloid leukemia ( AML ) can arise from genetic alterations in the bone marrow cells that give rise to blood cells. One fusion oncoprotein that is present in about 12% of human AML cases and is known to interfere with the process of normal blood cell development is called CBFB-SMMHC. Thus far, this protein has been very difficult to study in mouse models, as its expression causes embryonic lethality.

Lucio H. Castilla from the Program in Gene Function and Expression at the University of Massachusetts Medical School and colleagues created a conditional mouse model to analyze the preleukemic effects of CBFB-SMMHC on blood cell production and acute myeloid leukemia development in adult mice. The mouse model enabled the researchers to selectively turn on expression of CBFB-SMMHC in adult mice, thereby avoiding embryonic lethality of expression of this gene, and then study the effects.

The researchers found that CBFB-SMMHC induction was associated with a reduction of immature blood cells in the bone marrow and with the appearance of abnormal progenitor cells that are leukemic precursors. Mice expressing CBFB-SMMHC developed acute myeloid leukemia with a median latency of approximately five months, with the time of disease onset varying with the number of abnormal cells in the bone marrow. Interestingly, additional studies showed that the blood stem cell precursors that expressed CBFB-SMMHC were maintained at normal levels for long periods of time, but their ability to differentiate into multiple types of blood cells was severely compromised.

The researchers conclude that some leukemia fusion proteins that interfere with differentiation of blood cells may maintain normal numbers of blood stem cell precursors, but that these precursors may not be able to repopulate the blood adequately.
In addition, such fusion proteins may induce formation of abnormal precursor cells that are targets for development of acute myeloid leukemia, essentially existing as cancer causing "time bombs" in the bone marrow.

According to Castilla, " this model will be key for the study of early target genes in blood cell progenitors and the in vivo validation of cooperating oncogenes, as well as for the evaluation of candidate drugs for improved treatment of acute myeloid leukemia."

Source: Cancer Cell, 2006


XagenaMedicine2006